000126342 001__ 126342
000126342 005__ 20180913054717.0
000126342 0247_ $$2doi$$a10.1016/S0166-2236(00)01899-3
000126342 02470 $$2DAR$$a1981
000126342 02470 $$2ISI$$a000170674700014
000126342 037__ $$aARTICLE
000126342 245__ $$aRecombinant proteins for neurodegenerative diseases: the delivery issue
000126342 269__ $$a2001
000126342 260__ $$c2001
000126342 336__ $$aReviews
000126342 500__ $$aAuthor address: Gene Therapy Center, Lausanne University Medical Hospital, CHUV, 1011 Lausanne, Switzerland
000126342 520__ $$aTackling neurodegenerative diseases represents a formidable challenge for our ageing society. Recently, major achievements have been made in understanding the molecular mechanisms responsible for such diseases, and, simultaneously, numerous proteins such as neurotrophic factors, anti-apoptotic or anti-oxidant have been identified as potential therapeutic agents. Although many neurotrophic factors have been tested on individuals suffering from various neurodegenerative disorders, to date none has shown efficacy. Inadequate protein delivery is believed to be part of the problem. Recent improvements in pump technology, as well as in cell and gene therapy, are providing innovative ways to allow localized, regulatable delivery of proteins in brain parenchyma, opening new avenues for clinical trials in the not so distant future
000126342 6531_ $$aAnimals
000126342 6531_ $$aDrug Delivery Systems/instrumentation/methods
000126342 6531_ $$aGene Therapy/instrumentation/methods
000126342 6531_ $$aHumans
000126342 6531_ $$aNeurodegenerative Diseases/drug therapy
000126342 6531_ $$aRecombinant Proteins/administration & dosage
000126342 700__ $$0240206$$aAebischer, P.$$g104359
000126342 700__ $$aRidet, J.
000126342 773__ $$j24$$k9$$q533-540$$tTrends in neurosciences
000126342 909C0 $$0252067$$pLEN$$xU10457
000126342 909CO $$ooai:infoscience.tind.io:126342$$pSV$$preview
000126342 937__ $$aLEN-REVIEW-2008-006
000126342 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000126342 980__ $$aREVIEW